CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

被引：1

作者：

Liu, Wei ^{[1
]}

Huang, Wenyang ^{[1
]}

Lv, Rui ^{[1
]}

Liu, Huimin ^{[1
]}

Yi, Shuhua ^{[1
]}

Liu, Hong ^{[1
]}

Lv, Lulu ^{[2
]}

Qiu, Lugui ^{[1
]}

Wang, Jianxiang ^{[1
]}

Zou, Dehui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Juventas Cell Therapy Ltd, Tianjin, Peoples R China

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-167104

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4598 / 4599

页数：2

共 50 条

[21] CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview
Mohty, Mohamad
Dulery, Remy
Gauthier, Jordan
Malard, Florent
Brissot, Eolia
Aljurf, Mahmoud
Bazarbachi, Ali
Chabanon, Christian
Kharfan-Dabaja, Mohamed A.
Savani, Bipin N.
Huang, He
Kenderian, Saad S.
Perales, Miguel-Angel
Yakoub-Agha, Ibrahim
Nagler, Arnon
BONE MARROW TRANSPLANTATION, 2020, 55 (08) : 1525 - 1532
[22] CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview
Mohamad Mohty
Remy Dulery
Jordan Gauthier
Florent Malard
Eolia Brissot
Mahmoud Aljurf
Ali Bazarbachi
Christian Chabanon
Mohamed A. Kharfan-Dabaja
Bipin N. Savani
He Huang
Saad S. Kenderian
Miguel-Angel Perales
Ibrahim Yakoub-Agha
Arnon Nagler
Bone Marrow Transplantation, 2020, 55 : 1525 - 1532
[23] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients With Relapsed or Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 15 - 17
[24] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
Sano, Dahlia
Nastoupil, Loretta J.
Fowler, Nathan H.
Fayad, Luis
Hagemeister, F. B.
Lee, Hun Ju
Samaniego, Felipe
Wang, Michael
Rodriguez, Maria Alma
Iyer, Swaminathan P.
Parmar, Simrit
Steiner, Raphael
Nair, Ranjit
Adkins, Sherry
Arafat, Sara
Rao, Ahalya
Vallejo, Liliana
Hawkins, Misha
Chen, Yiming
Westin, Jason R.
Neelapu, Sattva S.
BLOOD, 2018, 132
[25] CAR T-Cell Therapy in Large B-Cell Lymphoma
Quintas-Cardama, Alfonso
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (11): : 1065 - 1065
[26] CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Retrospective Study
Zhao, Liping
Zhou, Qi
Chen, Chen
Ling, Zhuojun
Wang, Kai
Wu, Fan
Xu, Jinlong
Duan, Jiajia
Wang, Zelin
Wang, Quangang
Pan, Jing
BLOOD, 2023, 142
[27] Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Liang, Emily C.
Albittar, Aya
Huang, Jennifer J.
Hirayama, Alexandre, V
Kimble, Erik L.
Portuguese, Andrew J.
Chapuis, Aude
Shadman, Mazyar
Till, Brian G.
Cassaday, Ryan D.
Milano, Filippo
Kiem, Hans -Peter
Riddell, Stanley R.
Turtle, Cameron J.
Maloney, David G.
Gauthier, Jordan
BLOOD ADVANCES, 2023, 7 (22) : 6990 - 7005
[28] Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell Lymphomas
Schuster, Stephen J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 622 - 624
[29] Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report
Ababneh, Hazim S.
Johnson, P. Connor
Pursley, Jennifer
Patel, Chirayu G.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 48
[30] Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
Wang, Ying
Wei, Xudong
Yan, Dongmei
Zhang, Cheng
Zhou, Hongsheng
Tong, Chunrong
Mei, Heng
Jin, Jie
Niu, Ting
Liang, Aibin
Ren, Jienan
Deng, Yiping
Jin, Wei
Feng, Yi
Shi, Lin
Wang, Yongzeng
Haudenschild, Changting
Lv, Lulu
Wang, Jianxiang
BLOOD, 2022, 140 : 1598 - 1600

← 1 2 3 4 5 →